385 filings
Page 7 of 20
DEFA14A
dtmgx
30 Apr 21
Additional proxy soliciting materials
7:11am
8-K
2cw7vv3tv
30 Apr 21
Alkermes Announces Agreement with Sarissa Capital
7:10am
8-K
kytu4bhb3
28 Apr 21
Alkermes plc Reports First Quarter 2021 Financial Results
7:05am
8-K
3xn8 tozv
25 Mar 21
Regulation FD Disclosure
12:00am
8-K
jh4irjw
12 Mar 21
Entry into a Material Definitive Agreement
4:30pm
8-K
9cnji8ln
11 Feb 21
Results of Operations and Financial Condition
7:05am
8-K
2bb4386q r7hecm
11 Jan 21
Regulation FD Disclosure
7:00am
8-K
9nnj 69hss1q5u4xduvm
6 Jan 21
Alkermes Announces Updates to Executive Leadership Team
4:24pm
8-K
2lauq82 7pa
10 Dec 20
Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment
7:19am
8-K
ge4g5m6o 1qm
17 Nov 20
Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review
7:15am
8-K
4qopp36
29 Oct 20
Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations
7:06am
8-K
9k19c9t1j49t1n8fej
9 Oct 20
FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder
5:20pm
8-K
q9grp3cyc3o00k 9p
9 Sep 20
Other Events
5:00pm
S-8
dcptshr2zs3prsgu868n
29 Jul 20
Registration of securities for employees
5:09pm
S-8 POS
x051h1go
29 Jul 20
Registration of securities for employees (post-effective amendment)
4:51pm